Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
In fact as years go by, more & more medicines are needed
With the right combination of professional treatments and at-home care, you can enjoy not only the benefits of your weight loss but also a renewed confidence in your skins appearance
Additionally, the infusion of native human GIP (142) into cardiac myocytes isolated from embryonic mouse hearts inhibited the increase in brain natriuretic peptide (BNP) and transforming growth factor- (TGF- 1) mRNA expression induced by angiotensin II (Ang II) [13]
What we know The human study of eight breastfeeding mothers found undetectable levels in all milk samples
Liraglutide has been approved by the United States Food and Drug Administration (FDA) for long-term weight management (4)
